Handelsbanken Fonder AB Purchases 1,700 Shares of United Therapeutics Corporation $UTHR

Handelsbanken Fonder AB grew its position in United Therapeutics Corporation (NASDAQ:UTHR) by 15.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 12,600 shares of the biotechnology company’s stock after acquiring an additional 1,700 shares during the period. Handelsbanken Fonder AB’s holdings in United Therapeutics were worth $6,139,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Darwin Global Management Ltd. bought a new position in shares of United Therapeutics during the third quarter worth $317,617,000. Baillie Gifford & Co. bought a new position in shares of United Therapeutics during the fourth quarter worth $157,390,000. Balyasny Asset Management L.P. boosted its position in shares of United Therapeutics by 863.9% during the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after acquiring an additional 136,883 shares during the last quarter. Sofinnova Investments Inc. bought a new position in shares of United Therapeutics during the second quarter worth $34,055,000. Finally, Orbimed Advisors LLC bought a new position in shares of United Therapeutics during the third quarter worth $48,167,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 14,440 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $472.13, for a total transaction of $6,817,557.20. The SEC filing for this sale provides additional information. Insiders have sold 569,913 shares of company stock valued at $317,603,631 in the last quarter. 8.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Finally, Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Stock Up 0.5%

UTHR stock opened at $568.43 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a fifty day simple moving average of $563.25 and a two-hundred day simple moving average of $511.57. The firm has a market capitalization of $24.13 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the business earned $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.